Jess Rabourn, CFA

Jess Rabourn, CFA, serves as the CEO of WideTrial, Inc. since December 2017, focusing on improving drug development through innovative patient engagement. In addition, Jess is the Managing Partner at Ax-S Pharma, LLC, providing specialty consulting on Expanded Access clinical trials, and has held the position of Managing Director at the National Board of Early Access Medicine from December 2011 to April 2024, emphasizing education and policy support for this critical area in healthcare. Jessie also contributed as the Executive Producer of the Expanded Access Summit from March 2017 to July 2022, while co-founding PCUT BioPartners, Inc. and founding the Partnership for Compassionate Use Therapies. Previous roles include Vice President at Allianz Alternative Asset Management, Senior Associate at RCM Capital Management, and experience at Thomson Reuters and IFS International. Education was completed at the University of California, Davis, with a Bachelor's Degree in Economics.